Our R D software engineers are tasked with designing and developing innovative, breakthrough next-generation medical device software solutions that improve our core and disruptive products which improve the quality of patient lives around the world. The Interventional Oncology and Embolization (IO&E) unit has category leadership in minimally invasive therapies for cancer and vessel trauma, looking to continue to advance ways to support patients. Growth of the division is driven by unmet clinical need, under-diagnosed and under-treated patient populations, and heterogeneity of disease. IO&E offers innovations in embolization and interventional oncology.